Compare XZO & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XZO | PRCT |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2025 | 2021 |
| Metric | XZO | PRCT |
|---|---|---|
| Price | $22.54 | $32.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $27.00 | ★ $51.13 |
| AVG Volume (30 Days) | 198.6K | ★ 1.4M |
| Earning Date | 12-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 480.31 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | $210,669,000.00 | ★ $299,907,000.00 |
| Revenue This Year | $56.84 | $48.30 |
| Revenue Next Year | $13.24 | $29.44 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | ★ 138.35 | 50.07 |
| 52 Week Low | $12.92 | $27.80 |
| 52 Week High | $23.75 | $89.49 |
| Indicator | XZO | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.15 |
| Support Level | N/A | $31.70 |
| Resistance Level | N/A | $34.88 |
| Average True Range (ATR) | 0.00 | 1.63 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 0.00 | 13.00 |
Exzeo Group Inc provides turnkey insurance technology and operations solutions to insurance carriers and their agents based on a proprietary platform of purpose-built software and data analytics applications that are specifically designed for the property and casualty, or P&C, insurance ecosystem. Its Insurance-as-a-Service (IaaS) platform, which it refers to as the Exzeo Platform, currently includes nine configurable software and data analytics applications that are purpose-built to serve insurance companies and other customers in the insurance value chain. Through the Exzeo Platform, the company provides technology-based solutions and services for all operational and administrative activities and functions needed by P&C insurance carriers and their agents.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.